A study by the CDC and Washington University found COVID-19 significantly increases the risk of developing fatigue and chronic fatigue, with higher incidence rates compared to non-COVID-19 controls.
Cabozantinib Improves PFS for Advanced Neuroendocrine Tumors
Cabozantinib (Cabometyx) significantly improved progression-free survival (PFS) in patients with previously treated, progressive advanced extrapancreatic or pancreatic neuroendocrine tumors (NETs), according to final results from